ClinicalTrials.gg
Not yet recruitingNCT07693179NEOTHERMUpdated Sep 3, 2026

Assessment of Prolonged Pain in Infants With Excessive Crying: Contribution of Infrared Thermal Imaging - The NEOTHERM Pilot Study

An observational study in Excessive Crying and Prolonged Pain, sponsored by Centre Hospitalier de Saint-Denis. Not yet recruiting at 3 sites in France. Open to participants aged 2 Weeks to 6 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Centre Hospitalier de Saint-Denis · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
2 Weeks to 6 Weeks
Sex
All
01

Study summary

NEOTHERM is a multicenter, prospective, observational pilot study examining whether infrared thermal imaging (ITI) can contribute to the assessment of prolonged pain in infants with excessive crying. Thermal measurements of the face and body will be compared with scores obtained using the EDIN behavioral pain and discomfort scale. The study will also examine associations between ITI measures, EDIN scores, and hair cortisol concentrations as a biomarker of prolonged stress, and will describe early motor organization and psychomotor development using General Movements Assessment and Bayley-4. Eighty infants will be enrolled in two comparison groups based on daily crying duration and assessed longitudinally at two standardized visits. The main hypothesis is that ITI will identify cutaneous thermal changes associated with prolonged pain and that these measures will be associated with EDIN scores.

02

Conditions studied

  • Excessive Crying
  • Prolonged Pain

Browse trials for

Keywords

  • Infant
  • Excessive Crying
  • Prolonged Pain
  • Infrared Thermal Imaging
  • EDIN Scale
  • Hair Cortisol
  • General Movements Assessment
  • Early Neurodevelopment
  • Psychomotor Development
  • Chronic Stress
  • Multimodal Assessment
03

In context

Crying

39 studies on the registry are indexed under Crying; 8 are open to participants now.

Browse Crying studies →

Lead sponsor

Centre Hospitalier de Saint-Denis is the lead sponsor of 46 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Weeks to 6 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Experimental group: excessive crying duration

The study population will comprise 80 infants recruited prospectively from three participating centers. Infants will be enrolled at 2 to 6 weeks post-term in corrected age and reassessed at 10 to 14 weeks post-term in corrected age.

Based on the 7-day parental crying diary completed before the first assessment, infants will be classified into two predefined cohorts: an excessive-crying (EC) cohort and a typical-crying (TC) cohort, with 40 infants planned in each cohort.

Participants in the TC cohort will be matched to participants in the EC cohort according to corrected age at assessment (±1 week), sex when possible, gestational age at birth (±1 week), feeding modality, and maternal parity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants aged 2 to 6 weeks post-term in corrected age at the first assessment.
  • Born at or after 32 weeks' gestational age.
  • No known neurological or gastrointestinal disease.
  • Written from the holder(s) of parental authority.
  • Meeting the criteria for one of the following two cohorts:

    • Excessive-crying (EC) cohort: crying for more than 3 hours per day on at least 3 consecutive days during the 7 days preceding the assessment (modified Wessel criteria), together with at least two of the following three protocol-specified Rome IV-related features: crying without an apparent cause, inconsolable crying, and associated signs including agitation, facial flushing, clenched fists, and/or flexed legs.
    • Typical-crying (TC) cohort: crying for less than 2 hours per day during the week preceding the assessment.

Infants crying for 2 to 3 hours per day during the week preceding the assessment will not be included in either cohort.

Exclusion criteria

Exclusion criteria:

  • Confirmed cerebral lesions identified by ultrasound or magnetic resonance imaging.
  • Major congenital or chromosomal abnormalities.
  • Growth faltering.
  • Birth before 32 weeks' gestational age.
  • Holder(s) of parental authority who do not speak French.
  • Lack of written from the holder(s) of parental authority.
  • Lack of affiliation with a French social security scheme.
  • Any situation falling under specific legal protection provisions under French law.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Excessive-Crying (EC) Cohort

    Infants aged 2 to 6 weeks post-term (corrected age) at the first assessment, with crying lasting more than 3 hours per day on at least 3 consecutive days during the 7 days preceding the assessment (modified Wessel criteria). Infants must also meet at least two of the following three protocol-specified Rome IV-related features: crying without an apparent cause, inconsolable crying, and associated signs including agitation, facial flushing, clenched fists, and/or flexed legs. No intervention will be assigned. Participants will undergo the observational assessments specified in the study protocol.

  • Typical-Crying (TC) Cohort

    Infants aged 2 to 6 weeks post-term (corrected age) at the first assessment, with crying lasting less than 2 hours per day during the 7 days preceding the assessment. Participants in the TC cohort will be matched to participants in the EC cohort according to corrected age at assessment (±1 week), sex where possible, gestational age at birth (±1 week), feeding modality, and maternal parity. No intervention will be assigned. Participants will undergo the observational assessments specified in the study protocol.

06

What researchers measure

Primary outcomes

  1. Association Between Infrared Thermal Imaging Indices and EDIN Total Score

    Mean skin temperatures will be extracted from predefined body and facial regions of interest. Infrared thermal imaging indices will include absolute bilateral body temperature differences, central-to-peripheral temperature gradients, and intra-facial temperature gradients calculated relative to the forehead. An absolute temperature difference greater than 0.5°C will be considered an abnormal thermal asymmetry. The EDIN is a behavioral scale assessing facial expression, body movements, sleep, interaction, and consolability. Each item is scored from 0 to 3. Higher scores indicate greater pain- or discomfort-related behaviors; a total score of 5 or higher indicates probable prolonged pain. Concordance between infrared thermal imaging indices and EDIN total scores will be quantified using Spearman rank correlation coefficients at each assessment. Thermal images will be analyzed by an external assessor blinded to the EDIN score and cohort classification.

    Time frame: At baseline (T1) and approximately 8 weeks after baseline (T2)

Secondary outcomes

  1. Associations Between Hair Cortisol Concentration, Infrared Thermal Imaging Indices, and EDIN Total Score

    Hair cortisol concentration will be measured in pg/mg of hair from a small sample collected from the occipital region. Cortisol will be quantified using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). Hair cortisol concentration will be investigated as a biomarker of prolonged stress. Spearman correlation coefficients will be calculated between hair cortisol concentration, infrared thermal imaging indices, and EDIN total scores

    Time frame: At baseline (T1) and approximately 8 weeks after baseline (T2)

  2. General Movements Assessment Scores and Motor Patterns

    Spontaneous general movements will be recorded with the infant lying supine, wearing only a diaper or onesie, during 2 to 5 minutes of active wakefulness without crying, interaction, a pacifier, or hiccups. Recordings will be independently evaluated by two assessors trained in General Movements Assessment and blinded to cohort classification, EDIN scores, and infrared thermal imaging results. The General Movement Optimality Score-Revised (GMOS-R; maximum score 38) will be used at Visit 1. The Motor Optimality Score- Revised (MOS-R) will be used at Visit 2; scores of 25 to 28 are considered optimal, whereas lower scores indicate less optimal motor organization. Qualitative motor characteristics, including movement quality, variability, fluency, symmetry, posture, and atypical movement patterns, will also be described and compared between cohorts.

    Time frame: At baseline (T1); approximately 15, 30, and 45 days after baseline; and approximately 8 weeks after baseline (T2)

  3. Psychomotor Development Assessed Using the Bayley Scales of Infant and Toddler Development, Fourth Edition

    Psychomotor development will be assessed using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4). Five subtests will be administered: cognitive development, receptive communication, expressive communication, fine motor development, and gross motor development. Raw subtest scores will be converted to scalar and composite scores using the normative tables of the Bayley-4. Higher scores indicate better performance in the assessed developmental domain. Scores will be compared between the EC and TC cohorts. Scoring will be performed by an assessor blinded to cohort classification.

    Time frame: At baseline (T1) and approximately 8 weeks after baseline (T2)

  4. Associations Between Early Motor Organization and Prolonged Pain or Stress Indicators

    Associations between General Movements characteristics, GMOS-R or MOS scores, Bayley-4 scores, infrared thermal imaging indices, EDIN total scores, and hair cortisol concentrations will be examined using Spearman correlations and exploratory regression analyses.

    Time frame: From baseline (T1) through approximately 8 weeks after baseline (T2)

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jul 2028, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jul 9, 2026
StartEst.
Sep 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07693179
Lead sponsor
Centre Hospitalier de Saint-Denis
Collaborators
Ecole Pratique des Hautes Etudes
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Joëlle Provasi, PhD
Contact
joelle.provasi@ephe.psl.eu
+33 1 88 12 02 99
Alizée LORI, MD
Contact
alizee.lori@ch-stdenis.fr
+33 01 42 35 61 40

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion